PACIFIC EDGE LIMITED — Board/Management Information 2019

Oct 2, 2019

Company Announcement 2 October 2019

==> picture [236 x 58] intentionally omitted <==

DIRECTOR CHANGE: RESIGNATION OF JOHN DUNCAN

Pacific Edge Limited advises that John Duncan has notified the Board of his resignation as a Director of the company, effective immediately.

The Board thanks John for his service and wishes him well. John remains a supportive shareholder in the company.

ENDS

For more information contact:

Chris Gallaher Chairman Pacific Edge Ltd P: +61 417 556 691

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies.